Condition

Melanoma (Skin Cancer) clinical trials and research

• 36Clinical trials
• 6NIH research projects
• 12Countries

Newest Melanoma (Skin Cancer) clinical trials

All recruiting trials (36)

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)

  In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07740941

• Bexmarilimab plus nivolumab in solid tumors, melanoma, and NSCLC

  This trial tests whether adding bexmarilimab to nivolumab can help people with melanoma, non-small cell lung cancer, or other advanced solid tumors whose cancer stopped responding to immune therapy.

  Recruiting at 2 sites Phase 1/2 Institute of Cancer Research, United Kingdom · Manchester and 1 other locations · NCT07718243

• Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Systemic Therapy

  This study looks at how stereotactic radiosurgery for melanoma brain metastases works when patients are also receiving immunotherapy or targeted therapy.

  Recruiting at 2 sites European Institute of Oncology · Milan, Italy and 1 other locations · NCT07691255

• Fiber to boost gut bacteria and immunotherapy response in advanced melanoma

  In people with advanced melanoma starting immunotherapy, this trial tests whether increasing dietary fiber can grow beneficial gut bacteria and improve treatment response.

  Recruiting Phase 2 Radboud University Medical Center · Nijmegen, Gelderland and 1 other locations · NCT07686835

• High-fiber diet with short-term fasting during melanoma immunotherapy

  This study tests whether a high-fiber diet, with or without short-term fasting, can help people with melanoma better tolerate and respond to immune checkpoint inhibitors.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07680452

• Bright light therapy to help time immune therapy for melanoma and NSCLC

  A feasibility test of daily 60-minute bright light therapy before starting first-line immune checkpoint therapy for melanoma or NSCLC.

  Recruiting Weill Medical College of Cornell University · New York, New York · NCT07661966

• Gustabor: Tailored AI Nutrition for Taste Changes During Cancer Therapy

  This trial tests whether personalized, AI-assisted dietary advice helps people with taste changes from cancer treatment compare to general dietary guidance.

  Recruiting at 2 sites Wuerzburg University Hospital · Augsburg, Bavaria and 5 other locations · NCT07649681

• Cadonilimab plus high-dose interferon in neoadjuvant treatment for stage III/IV melanoma

  This trial tests whether giving cadonilimab with high-dose interferon before surgery can shrink tumors in people with stage III or resectable stage IV melanoma and whether it is safe.

  Recruiting Early Phase 1 Xijing Hospital · Xi'an · NCT07586904

• Low-branch-chain amino acid diet with anti-PD-1 therapy before surgery in stage III melanoma

  This study tests whether a diet low in branched-chain amino acids, given with an anti-PD-1 antibody before surgery, is safe and helps improve responses in patients with stage III melanoma.

  Recruiting Xijing Hospital · Xi'an · NCT07586891

• Blood-based multi-omics for melanoma biomarker discovery

  This study will test whether combining circulating tumor DNA, circulating tumor cells, and exosome analyses can track response and predict outcomes in adults with acral or cutaneous melanoma starting first-line immunotherapy.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07584291

• Bone density changes with anti-PD-1 immunotherapy

  This pilot will test if anti-PD-1 immunotherapy changes bone density in adults starting approved anti-PD-1 treatment for certain early-stage cancers.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07555210

• Omitting re-excision after complete primary melanoma excision

  This trial tests whether people with pT1b–pT4b cutaneous melanoma whose tumors were completely removed can safely skip the usual re-excision surgery.

  Recruiting at 10 sites Phase 3 The Netherlands Cancer Institute · 's-Hertogenbosch and 20 other locations · NCT07530887

• Personal cancer risk testing using genetic, blood, and tumor monitoring

  This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT07469709

• One-dose pembrolizumab before surgery for high-risk localized melanoma

  This trial gives one dose of pembrolizumab six weeks before surgery to see if it helps adults with high‑risk melanoma that appears confined on scans.

  Recruiting Phase 2 Universitair Ziekenhuis Brussel · Jette, Brussels Capital · NCT07448831

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• TGI-5 alone and with nivolumab for advanced or metastatic solid tumors

  This trial tests whether TGI-5 by itself or combined with nivolumab is safe and can shrink tumors in adults with advanced or metastatic colorectal cancer, melanoma, hepatocellular carcinoma, or non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1 Hefei TG ImmunoPharma Co., Ltd. · Shanghai · NCT07376707

• Predicting who responds to anti-PD-1/PD-L1 therapy using blood extracellular vesicle tests

  This study tests whether immune biomarkers found in blood extracellular vesicles can predict who with NSCLC or unresectable melanoma will respond to anti-PD-1/PD-L1 therapies.

  Recruiting at 2 sites Centre Georges Francois Leclerc · Besançon and 4 other locations · NCT07376512

• One-dose pembrolizumab before surgery for thick primary (Stage IIb/c) melanoma

  This trial tests whether giving one dose of pembrolizumab before surgery helps adults with biopsy-proven Stage IIb/c primary cutaneous melanoma.

  Recruiting Phase 2 Vastra Gotaland Region · Gothenburg · NCT07349303

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• AMXT 1501 and DFMO added to standard treatments for advanced breast cancer and melanoma

  This will test whether adding two oral drugs, AMXT 1501 and DFMO, to standard therapies helps people with advanced ER+ HER2- breast cancer or unresectable/metastatic melanoma.

  Recruiting at 20 sites Phase 1/2 Aminex Therapeutics, Inc. · Tucson, Arizona and 19 other locations · NCT07287917

• Testing a digital remote monitoring tool for patients with melanoma on immunotherapy

  A digital remote monitoring program using wearables and self-reports is being tested to see if it’s easy to use and helps manage symptoms and quality of life for melanoma patients on immunotherapy.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07280715

• Confocal imaging and genetic testing of atypical moles and early melanoma

  This project will try to see if noninvasive confocal images of suspicious moles match genetic changes from sequencing in adults who are having the lesions removed.

  Recruiting University of Modena and Reggio Emilia · Modena, Mo · NCT07277920

• Does immunotherapy for melanoma affect reproductive organs in premenopausal women and men?

  This study will see if immune checkpoint inhibitor treatment for melanoma changes sex hormone levels and reproductive organ function in adults receiving these drugs.

  Recruiting Peter MacCallum Cancer Centre, Australia · Sydney, New South Wales and 5 other locations · NCT07138222

• LNS8801 alone or with pembrolizumab for people whose melanoma has stopped responding.

  This trial will test whether LNS8801, by itself or combined with pembrolizumab, can keep melanoma that progressed after anti‑PD‑1 therapy from growing.

  Recruiting at 9 sites Phase 2/3 Linnaeus Therapeutics, Inc. · Newport Beach, California and 8 other locations · NCT06624644

• Using AI to diagnose melanoma in young patients

  This study is testing if artificial intelligence can help doctors better identify melanoma in children and young adults by looking at skin images.

  Recruiting German Cancer Research Center · Tübingen and 2 other locations · NCT06621810

• Creating a database for melanoma in children and young adults

  This study is trying to create a detailed database for melanoma in kids and young adults to see how well they do and improve treatment options for them.

  Recruiting Fundacion Clinic per a la Recerca Biomédica · Barcelona, Catalonia · NCT06608420

• Using breath and skin tests to detect melanoma early

  This study is testing if a breath analyzer and a skin patch can help find advanced melanoma earlier by checking for certain chemicals in your breath and skin.

  Recruiting at 2 sites Fundacion Clinic per a la Recerca Biomédica · Barcelona and 2 other locations · NCT06605443

• Collecting samples from patients with certain types of cancer to improve detection and treatment.

  This study is collecting blood and tissue samples from patients with certain types of cancer to see if it can help improve how we detect cancer and understand the risk of it coming back.

  Recruiting at 47 sites Paradigm Health · Birmingham, Alabama and 46 other locations · NCT06605404

• Combining alpelisib and pembrolizumab for advanced breast cancer and melanoma

  This study is testing a new combination treatment of alpelisib and pembrolizumab to see how safe it is for people with advanced melanoma and triple-negative breast cancer.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT06545682

NIH-funded research (6)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• CivaDerm: a new four-day skin cancer radiation bandage

  A new four‑day radiation bandage for non-melanoma skin cancer aims to treat facial and other areas without multiple clinic visits or big scars.

  NIH research Civatech Oncology, INC. · Morrisville, UNITED STATES · NIH-11408990

• MOSAIC II: MAP Wound Matrix to speed graft readiness after non-melanoma skin cancer surgery

  A randomized trial tests a moldable wound scaffold (MAP Wound Matrix) to speed healing and time to graft-ready skin after head and neck cancer surgeries in adults.

  NIH research Tempo Therapeutics, INC. · San Diego, UNITED STATES · NIH-11406980

• Low-energy skin radiation patches for treating non-melanoma skin cancer

  A patient-friendly device idea uses a patch to deliver a tiny amount of radiation right at the skin to treat non-melanoma skin cancer in as few visits.

  NIH research Oncopatch, INC · Centennial, United States · NIH-11314378

• Safer medicines to prevent basal and squamous (non‑melanoma) skin cancer

  Researchers are developing new, non‑toxic oral rexinoid medicines aimed at preventing basal cell and squamous cell skin cancers, especially for people with weakened immune systems like organ transplant recipients.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11289434

• Creating safe drugs to prevent non-melanoma skin cancer

  This study is working on new medications to help prevent skin cancer in people with weakened immune systems, like those who have had organ transplants, by creating safer and more effective options that don’t have the usual side effects of current treatments.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11015805

• New ways to prevent non-melanoma skin cancer

  This study is looking for new ways to help prevent non-melanoma skin cancers, like basal cell and squamous cell carcinoma, by understanding how these cancers develop and testing new treatments that could lower your risk.

  NIH research University of Arizona · Tucson, United States · NIH-10686365

Related topics

Quick answers

How many Melanoma (Skin Cancer) clinical trials are recruiting right now?

36, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in United States (11 trials), China (8 trials), Italy (4 trials), Spain (3 trials), Germany (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 2: 5, Phase 1: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →